Treating human cancer by targeting EZH2
Mengfei Xu,Chunyan Xu,Rui Wang,Qing Tang,Qichun Zhou,Wanyin Wu,Xinliang Wan,Handan Mo,Jun Pan,Sumei Wang
DOI: https://doi.org/10.1016/j.gendis.2024.101313
IF: 7.376
2024-05-07
Genes & Diseases
Abstract:Enhancer of zeste homolog 2 (EZH2), an epigenetic regulator that primarily inhibits downstream gene expression by tri-methylating histone H3, which is usually overexpressed in tumors and participates in many processes such as tumor occurrence and development, invasion, migration, drug resistance, and anti-tumor immunity as an oncogene, making it an important biomarker in cancer therapy. Collectively, several transcription factors and RNAs cooperate to facilitate the elevated expression of EZH2 in cancer. Although the significance of blocking EZH2 in cancer for inhibiting cancer progression is widely recognized, the clinical application of EZH2 inhibitors continues to encounter numerous challenges. In this review, drawing upon our comprehensive understanding of the factual underpinnings of EZH2's role in cancer, we aim to clarify the crucial importance of targeting EZH2 in cancer treatment. Furthermore, we summarize the current research landscape surrounding targeted EZH2 inhibitors and offer insights into potential future applications of these inhibitors.
genetics & heredity,biochemistry & molecular biology